Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

Bookmark and Share
Published: 10 Oct 2016
Views: 1091
Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Dr Ravaud presents, at a press conference at ESMO 2016, results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients.

This phase III trial found a longer disease-free survival in the sunitinib arm, and Dr Ravaud describes this extension with the manageable toxicity profile as recommending factors for sunitinib in adjuvant therapy.

Dr Ravaud discussed these results further with ecancer here, and the data is available in ecancer news coverage here.